VKTX VK2735: 90% Maintenance, $4.9B Market Cap

The biggest criticism of GLP-1 drugs is not efficacy. It is what happens when you stop taking them, because the weight comes back. Viking Therapeutics just answered that question with a number, and it is a number no one else in the class has printed. VK2735 kept up to 90% of weight loss after switching patients to once-monthly dosing, against 61% for patients switched to placebo. The market loved it, then gave a chunk of it back when Viking priced a $500 million raise into the rally.

The data, in numbers

Viking’s maintenance study put roughly 180 obese adults on weekly VK2735 for 21 weeks, then randomized them to less frequent regimens or placebo for another 12. The induction phase did what VK2735 always does: 16% to 19% weight loss by week 21, versus effectively zero on placebo, with the 17.5 mg dose at 17.8% and the 20 mg dose at 18.7%, both placebo-adjusted and significant at p less than 0.0001. By week 21, 98% of treated patients had lost at least 5% of body weight, 90% had lost at least 10%, 65% at least 15%, and 32% at least 20%. Full data is in Viking’s topline release.

The maintenance phase is the new part. Patients transitioned to every-other-week dosing held up to 97% of their week 21 weight loss, and the monthly regimens held up to 90%, versus 61% for placebo. Separation from placebo appeared as early as four weeks after the transition. GI side effects during maintenance ran similar to placebo, which is the tolerability signal that matters most for long-term adherence.

Then there is the exploratory arm, and it is the quiet headline. Patients who stayed on 17.5 mg weekly for the full 33 weeks reached roughly 22% placebo-adjusted weight loss with no plateau. That is tirzepatide territory, arrived at faster. Lilly’s tirzepatide hit 22.5% at 72 weeks in SURMOUNT-1 and 20.2% versus semaglutide’s 13.7% in the SURMOUNT-5 head-to-head. VK2735 is showing the same efficacy class, compressed into less than half the time, with a half-life long enough to support monthly dosing.

Why maintenance is the actual battleground

The obesity market is not really about who can drop the most weight in a trial. It is about who keeps patients on therapy, because weight maintenance, not induction, drives the multi-year revenue stream that justifies a $100 billion market. Dropout is the industry’s dirty secret: real-world persistence on weekly GLP-1 injections is poor, and every patient who stops gets the weight back.

A monthly or every-other-week option changes that calculus. If a patient can hold 90% of their loss on a once-monthly shot instead of a weekly one, adherence gets easier and the commercial value per patient goes up. Viking’s chief executive framed it exactly that way, and the maintenance data gives the company its clearest differentiator yet against the weekly injectables from Lilly and Novo.

It also strengthens the pairing with Viking’s oral tablet. The oral VK2735 hit 12.2% weight loss at 13 weeks in its own Phase 2, and Viking is pushing that formulation toward Phase 3. A monthly injectable for maintenance plus a daily pill for induction is a franchise structure neither Lilly nor Novo currently offers.

The stock surge, and the raise that clipped it

VKTX jumped about 35% on the readout, from roughly $30 to a $41.65 close on 41 million shares traded. Then Viking priced an upsized $500 million offering across common stock and convertible notes, and the shares gave back to around $36.75 as the market absorbed the dilution. The company entered the back half of 2026 with about $502 million in cash, so the raise roughly doubles the balance sheet to something near $1 billion.

That is the right strategic move, even if it cost shareholders 12% off the top. VK2735’s Phase 3 VANQUISH program is expensive. VANQUISH-1 enrolled about 4,500 obese or overweight adults, VANQUISH-2 about 1,000 with type 2 diabetes, both 78-week studies with readouts in 2027. A well-funded balance sheet going into those readouts is worth more than avoiding dilution today. Management is loading up for the registrational trial that actually decides the company’s fate.

The valuation case, and its limits

Viking now trades at a $4.9 billion market cap. That is the question in the title. Pre-data the stock sat near $30, about a $3.5 billion market cap. The maintenance readout added roughly $1.4 billion of enterprise value in two days, which is the market saying the adherence story is real. For a clinical-stage company with zero revenue, $4.9 billion is a bet that VK2735 becomes a top-three obesity franchise.

The bull case has a real number in it. If VK2735 delivers tirzepatide-adjacent efficacy with a maintenance moat, peak sales north of $5 billion are plausible in a market projected to clear $100 billion. At $4.9 billion, Viking is pricing roughly one times a discounted peak sales figure, cheap if the drug is as good as the 33-week exploratory arm suggests and expensive if VANQUISH disappoints.

Put the comp in perspective. Tirzepatide generated a combined $36.5 billion across Mounjaro and Zepbound in 2025, making it the highest-grossing drug franchise in the industry, and it pushed Eli Lilly past a $1 trillion market cap. Novo Nordisk is heading the other direction, guiding 2026 sales down 5% to 13% after the White House pricing deal cut semaglutide prices, and its shares tumbled 18% on the warning. Viking at $4.9 billion is a rounding error against either incumbent, which is the point: if VK2735 works, the re-rating room is enormous.

The honest caveat is that none of this is registrational data yet. The maintenance study is Phase 2, exploratory, and small. The registrational question, does VK2735 beat placebo at scale in VANQUISH with a tolerable GI profile, is still unanswered. The 22% number comes from an exploratory cohort, not the primary endpoint of a registrational trial. Lilly’s retatrutide posted up to 22.6% weight loss and is filing in 2027, a reminder that the incumbents are not standing still, and the oral and amylin second wave is right behind.

Risks

VANQUISH itself is the risk that matters. A 78-week, placebo-controlled Phase 3 in 4,500 patients can find GI tolerability problems or a weight-loss curve that plateaus earlier than the exploratory arm suggested. The dilution treadmill is another. The convertible note component of the raise could convert and add shares over time, and Viking will likely need additional capital before the 2027 readouts. Competition is tightening, too. Tirzepatide already owns the efficacy high ground, retatrutide is coming, and Novo’s oral and Lilly’s pill programs are targeting the same adherence wedge Viking is trying to claim with monthly dosing. The myostatin-adjunct angle in the muscle preservation roundup shows the category keeps fragmenting.

Verdict

Viking is worth owning here, but sized like the binary it is. The maintenance data is a genuine, differentiated result that answers the class’s biggest objection, and the $500 million raise de-risks the runway into VANQUISH even as it dilutes. At $4.9 billion, you are not paying for proof; you are paying for the best adherence story in obesity plus efficacy that looks like tirzepatide’s.

The right move is a small position, one to two percent of a biotech portfolio, bought on pullbacks rather than chased after a 35% spike. The 2027 VANQUISH readouts are the binary that re-rates this either toward a $20 billion plus obesity franchise or back toward a single-digit stock. For now, Viking just answered the “what happens when you stop” question. The answer is good enough to hold, not good enough to bet the house on.